本帖最后由 老马 于 2012-1-13 21:20 编辑 6 Q B7 n; }; i: O! {1 f
6 S) ?: {+ u" U) O- E& ~5 P2 ~3 W爱必妥和阿瓦斯丁的比较9 `; u9 W3 I, a5 k; u6 x! ^6 ~/ s
* K( R) ?* e4 A' D. V& mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
% Q% y B- H# ~! [# `& c7 Q
( f C {& M2 E9 D
# _4 B- v9 z: u) C" P9 Y5 I mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) h8 R6 q" M1 M# N/ f5 l( o
================================================== {: F: y8 t& Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 F0 y6 V1 b, U3 R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- V2 B2 c( w$ c5 w4 i+ o1 |+ xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
@$ e$ v& T) I; D" i/ t
|